1261396-60-4
Chemical Structure
Cyclobenzaprine-d6
- CAS No.: 1261396-60-4
- Formula:C20H15D6N
- Molecular Weight:281.42
IUPAC Name: 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-bis(methyl-d3)propan-1-amine
InChIKey: JURKNVYFZMSNLP-WFGJKAKNSA-N
SMILES: [2H]C([2H])([2H])N(C([2H])([2H])[2H])CC/C=C1C2=CC=CC=C2C=CC3=CC=CC=C3/1
Biological Activity: Cyclobenzaprine-d6 is the deuterium labeled Cyclobenzaprine. Cyclobenzaprine (MK130) hydrochloride is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine hydrochloride acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Cyclobenzaprine hydrochloride also possesses antiparasitic activity. Cyclobenzaprine hydrochloride holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cyclobenzaprine-d6 | Cyclobenzaprine-d6 is the deuterium labeled Cyclobenzaprine. Cyclobenzaprine (MK130) hydrochloride is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine hydrochloride acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Cyclobenzaprine hydrochloride also possesses antiparasitic activity. Cyclobenzaprine hydrochloride holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cyclobenzaprine | Cyclobenzaprine (MK130) is an orally active 5-HT2 receptor antagonist. Cyclobenzaprine acts centrally, providing skeletal muscle relaxation, alleviating muscle spasms, and reducing pain. Cyclobenzaprine also possesses antiparasitic activity. Cyclobenzaprine holds promise for research in the fields of acute, painful skeletal muscle disorders and infectious diseases. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Kobayashi, H., Y. Hasegawa, and H. Ono, Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol, 1996. 311(1): p. 29-35. [Content Brief]
- [2]. Honda, M., T. Nishida, and H. Ono, Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol, 2003. 458(1-2): p. 91-9. [Content Brief]
- [3]. Borenstein D G & Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials[J]. Clinical therapeutics, 2003, 25(4): 1056-1073. [Content Brief]
- [4]. Share N N, et al. Cyclobenzaprine: a novel centrally acting skeletal muscle relaxant[J]. Neuropharmacology, 1975, 14(9): 675-684. [Content Brief]
- [5]. Cunha-Júnior EF, et al. Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice. PLoS Negl Trop Dis. 2017 Jan 3;11(1):e0005281. [Content Brief]
Keywords
